Aetna, Novartis strike deal on Entresto

Aetna Inc. (NYSE:AET) told BioCentury on Friday that it struck an outcomes-based pricing deal with Novartis AG (NYSE:NVS; SIX:NOVN) for heart failure drug Entresto sacubitril/valsartan.

Novartis agreed to an undisclosed base rebate on the drug that will increase or decrease based on the number of patients receiving Entresto who are hospitalized for heart failure. ...